To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) was off $1.48 (58%) to $1.06 on Wednesday after receiving a complete response letter from FDA for an NDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). According to the company, FDA said the authenticity of the drug products used in Adventrx's bioequivalence trial could not be verified following inspections at clinical sites. The agency said the trial will need to be repeated. Adventrx lost $1.40 (57%) to $1.06 for the week.

Affymax Inc. (NASDAQ:AFFY) fell $0.68 (13%) to $4.51 last week, when FDA set a March 27, 2012, PDUFA date for an NDA for peginesatide

Read the full 1037 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers